SCHEMBL401149

SCHEMBL401149

NCc1nccnc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29524134 1.00
Hydrochloric Acid SCHEMBL29522718 0.97 LOX (0.35)
Hydrochloric Acid SCHEMBL29444594 0.97 LOX (0.35)
Hydrochloric Acid SCHEMBL400450 0.97 LOX (0.35)
Hydrochloric Acid SCHEMBL593446 0.97 LOX (0.35)
SCHEMBL20240844 0.80 HRH1 (0.38)
SCHEMBL8332978 0.80 LOXL2 (0.36)
SCHEMBL16701558 0.79
SCHEMBL2021260 0.76
SCHEMBL23212103 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10793576-B2 Compound used as Bruton's tyrosine kinase inhibitor and preparation method and application thereof CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD. (CN) 2020-10-06 US claimed
US-20190315758-A1 COMPOUND USED AS BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD. (CN) 2019-10-17 US claimed
EP-2038264-B1 TETRAZOLE-SUBSTITUTED ARYLAMIDES HOFFMANN LA ROCHE (CH) 2016-10-26 EP claimed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
EP-4719606-A2 GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2026-04-08 EP disclosed
EP-3858833-B9 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2026-03-11 EP disclosed
US-20260001885-A1 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS MERCK SHARP & DOHME (NL) 2026-01-01 US disclosed
EP-3858833-B1 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2025-10-22 EP disclosed
US-12291534-B2 Aminonorbornane derivative and manufacture method therefor and use thereof TRANSTHERA SCIENCES (NANJING), INC. (CN) 2025-05-06 US disclosed
WO-2025067411-A1 NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京普祺医药科技股份有限公司 2025-04-03 WO disclosed
US-12162890-B2 Heteroaromatic NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2024-12-10 US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 US disclosed
EP-1740591-A1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2007-01-10 EP disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 US disclosed
EP-1675860-A2 IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-07-05 EP disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed
WO-2005097800-A1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-10-20 WO disclosed
WO-2005037836-A2 IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-04-28 WO disclosed